Skip to main content
Premium Trial:

Request an Annual Quote

OriGene Raises $16M to Continue Building Antibody Collection

Premium

This story originally ran on March 18.

OriGene Technologies this week announced that it has raised $16 million in its completed Series B financing round.

The proceeds will be used to continue building the company's TrueMab monoclonal antibody collection. In a statement, OriGene said that it aims to build a monoclonal antibody collection that will cover the entire human genome of about 20,000 genes or most of the human proteome.

"The funding will propel us closer to meeting our goal," Wei-Wu He, OriGene's chairman and CEO, said.

IDG-Accel, SBI &TH Venture Capital Enterprise, and Zero2IPO led the round. Previous investors Morningside Venture Investments and President International Development also participated in the round.

According to OriGene, the TrueMab antibodies will be "significantly different" from other antibodies on the market. The company is using authentic human full-length proteins as immunogens in the manufacturing process. As a result, the TrueMab antibodies have been "proven far superior in quality" compared to small peptide-generated monoclonal and polyclonal antibodies, "especially in applications such as flow cytometry and multiplex ELISA assays," OriGene said.

In November, the Human Protein Atlas said it had adopted OriGene's Verify Tagged Antigen over-expression lysates, full-length human proteins for functional studies and antibody validation, and increased the validation success rate to 80 percent from 30 percent [See PM 11/13/09].

Based in Rockville, Md., OriGene calls itself a gene-centric life sciences firm. Its product line includes more than 5,000 purified human proteins and the world's largest cDNA and shRNA clone collections.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.